Safety and Immunogenicity of the Quadrivalent HPV Vaccine in Japanese Boys: a Phase 3, Open-Label Study.
Murata, Shinya; Takeuchi, Yuzuru; Yamanaka, Kou; Hayakawa, Jun; Yoshida, Masashige; Yokokawa, Ruriko; Wakana, Akira; Sawata, Miyuki; Tanaka, Yoshiyuki.
Jpn J Infect Dis
; 72(5): 299-305, 2019 Sep 19.
Artigo em Inglês | MEDLINE | ID: mdl-31155600
Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.
Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
The safety and immunogenicity of Quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus.
Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females.
Eliciting adverse effects data from participants in clinical trials.
Predicting serious rare adverse reactions of novel chemicals.
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.